ArticleAmerican journal of translational research2021
LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Blocking METTL3-mediated lncRNA FENDRR silence reverses cisplatin resistance of lung adenocarcinoma through activating TFRC-mediated ferroptosis pathway.Journal of molecular histology · 2024Article
- Deciphering the nexus between long non-coding RNAs and endoplasmic reticulum stress in hepatocellular carcinoma: biomarker discovery and therapeutic horizons.Cell death discovery · 2024Review
- The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.International journal of molecular sciences · 2024Article
- Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNon-small cell lung cancer (NSCLC) is highly metastatic that can lead to high fatality rate. This study aimed at investigating the possible role of LncRNA TPTEP1 (TPTEP1) in NSCLC progression.
methodsCell proliferation was determined by MTT and colony formation assays. Transwell and scratch assays were adopted to assess cellular metastasis. RT-qPCR and western blot were used to detect TPTEP1 expression transcriptionally and translationally, respectively. The dual luciferase reporter assay and RNA immunoprecipitation assay were used to identify the specific target relationships.
resultsCompared with the normal adjacent tissues, the expressions of TPTEP1 and LATS2 were significantly down-regulated in the NSCLC tissues, while the expression of miR-761 was significantly increased. Overexpression of TPTEP1 exhibited substantial antitumor effects on NSCLC, including inhibition of cell proliferation and metastasis, which was achieved by targeting miR-761 and subsequently attenuated the expression of LATS2. LATS2 was identified as a direct target of miR-761. Overexpression of miR-761 could significantly block the inhibitory effects of TPTEP1 on NSCLC, which clearly indicated that miR-761 played an oncogenic role in promoting proliferation and metastasis, while its downstream factor, LATS2, exerted opposite effects.
conclusionThe study showed that TPTEP1 played an inhibitory role in cancer progression of NSCLC cells by regulating miR-761/LATS2 cascade, thereby highlighting the potential therapeutic significance of TPTEP1/miR-761/LATS2 axis.
Indexed as
Identifiers
34539985PMC8430104W3200604249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.